Acute and chronic graft versus host disease after hematopoietic stem cell transplant

Authors

  • Vaneuza A. M. Funke Professor of Hematology and Head of Adult HSCT center at Federal University of Paraná
  • Maria Claudia Rodrigues Moreira Hematologist at Centro de Transplante de Medula Óssea (CEMO) - National Institute of Cancer (INCA) and Federal University of Rio de Janeiro
  • Afonso Celso Vigorito Hematologist and Supervisor of HSCT center at UNICAMP (Campinas, São Paulo)

DOI:

https://doi.org/10.46765/2675-374X.2020v1n1p53-66

Keywords:

Graft versus host disease, Hematopoietic stem cell transplant

Abstract

Graft versus host disease is one of the main complications of Hematopoietic stem cell, in­volving about 50% to 80% of the patients. Acute GVHD clinical manifestations and therapy is discussed, as well as new NIH criteria for the diagnosis and classification of chronic GVHD. Therapy for both refractory chronic and acute GVHD is an important field of discussion once there is no superiority for the majority of the agents after primary therapy has failed. Hence, this review is meant to be a useful tool of consultation for clinicians who are dealing with this complex complication.

Downloads

Published

07/06/2020

How to Cite

Funke, V. A. M., Moreira, M. C. R., & Vigorito, A. C. (2020). Acute and chronic graft versus host disease after hematopoietic stem cell transplant. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(2), 53–66. https://doi.org/10.46765/2675-374X.2020v1n1p53-66

Issue

Vol. 1 No. 2 (2020): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

Most read articles by the same author(s)